Covered recipient · General Payments record
SURESH G NAIR
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$295.85
4 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $252.60 | 3 |
| Education | $43.25 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Exelixis Inc. | $175.00 | 1 |
| HISTOSONICS, INC. | $43.84 | 1 |
| AstraZeneca Pharmaceuticals LP | $43.25 | 1 |
| Immunocore Limited | $33.76 | 1 |
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SURESH G NAIR
NPI 1669423711 · CMS profile ID 166428
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
ALLENTOWN, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1669423711?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SURESH G NAIR, NPI 1669423711, CMS profile ID 166428. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669423711?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). SURESH G NAIR, NPI 1669423711, CMS profile ID 166428. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669423711?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- SURESH G NAIR, NPI 1669423711, CMS profile ID 166428, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1669423711?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
4 matching records · $295.85 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–4 of 4.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $43.25 | 11/25/2025 | Education | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206360854 | CMS |
| Immunocore Limited | $33.76 | 09/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235826293 | CMS |
| Exelixis Inc. | $175.00 | 05/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218805881 | CMS |
| HISTOSONICS, INC. | $43.84 | 01/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233991426 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $194,965.34 | 40 |
| PY2024 | Principal investigator | $148,310.84 | 44 |
| PY2023 | Principal investigator | $382,804.46 | 29 |
| PY2022 | Principal investigator | $135,383.95 | 27 |
| PY2021 | Principal investigator | $617,414.43 | 31 |
| PY2020 | Principal investigator | $541,006.34 | 33 |
| PY2019 | Principal investigator | $398,239.66 | 27 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
31 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $8,022.20 | 12/31/2021 | Covered Recipient Teaching Hospital LEHIGH VALLEY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma mRCC KEYNOTE-426 | No dispute reported | 06/30/2026 | 848745633 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $4,953.27 | 12/31/2021 | Covered Recipient Teaching Hospital Lehigh Valley | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma mRCC KEYNOTE-426 | No dispute reported | 06/30/2026 | 848745641 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $16,797.54 | 12/31/2021 | Covered Recipient Teaching Hospital LEHIGH VALLEY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy | No dispute reported | 06/30/2026 | 848753351 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $8,632.38 | 12/31/2021 | Covered Recipient Teaching Hospital LEHIGH VALLEY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy | No dispute reported | 06/30/2026 | 848753355 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $156.82 | 12/31/2021 | Covered Recipient Teaching Hospital LEHIGH VALLEY | A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus DNX-2401 with Pembrolizumab Keytruda for Recurrent Glioblastoma or Gliosarcoma | No dispute reported | 06/30/2026 | 848760067 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $56,114.75 | 12/15/2021 | Covered Recipient Teaching Hospital Lehigh Valley | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy | No dispute reported | 06/30/2026 | 848753347 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $163.00 | 11/12/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Ph III Adjuvant Melanoma Monotherapy | No dispute reported | 06/30/2026 | 859043007 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $652.00 | 11/12/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Phase III RCC 1L Combo | No dispute reported | 06/30/2026 | 859043009 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,000.00 | 11/12/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Ph IIB Hodgkins Lymphoma | No dispute reported | 06/30/2026 | 859043013 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $263.00 | 11/12/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Phase III 1L GBM Methylated nivo mono chemo RT | No dispute reported | 06/30/2026 | 859043021 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $50.00 | 10/04/2021 | Covered Recipient Teaching Hospital LEHIGH VALLEY | A Phase I,II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma | No dispute reported | 06/30/2026 | 848742831 |
| Principal investigator 1 | ABBVIE INC. | $2,600.00 | 09/08/2021 | Covered Recipient Teaching Hospital LEHIGH VALLEY | A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC) | No dispute reported | 06/30/2026 | 792386189 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $450,286.00 | 07/29/2021 | Non-covered Recipient Entity Memorial Sloan Kettering Cancer Center | Phase III Nivo Ipi vs Placebo in Adjuvant RCC | No dispute reported | 06/30/2026 | 819896721 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,500.00 | 06/03/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Phase III NSCLC 1L, sq anti-PD-1 vs platinum doublet PDL-1 | No dispute reported | 06/30/2026 | 819885973 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 05/26/2021 | Covered Recipient Teaching Hospital LEHIGH VALLEY | A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC) | No dispute reported | 06/30/2026 | 792386177 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,000.00 | 04/29/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Phase III MEL 1L, PD-1 vs Ipi vs. PD-1 Ipi | No dispute reported | 06/30/2026 | 819885933 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $7,150.00 | 04/29/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Phase IIB Hodgkins Lymphoma | No dispute reported | 06/30/2026 | 819885957 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,500.00 | 04/12/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Ph IIB NSCLC 3L squamous refractory | No dispute reported | 06/30/2026 | 819885945 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,500.00 | 03/29/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Phase II Sequential Ipi - Anti-PD-1 | No dispute reported | 06/30/2026 | 819885873 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $598.12 | 03/09/2021 | Non-covered Recipient Entity Lehigh Valley Hospital | Phase III Nivo Ipi vs Placebo in Adjuvant RCC | No dispute reported | 06/30/2026 | 819896127 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,815.00 | 03/01/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Phase III RCC 1L Combo | No dispute reported | 06/30/2026 | 819885867 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,000.00 | 03/01/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Phase III NSCLC 1L combo | No dispute reported | 06/30/2026 | 819885879 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,289.00 | 02/05/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Phase III 1L GBM Methylated nivo mono chemo RT | No dispute reported | 06/30/2026 | 819885915 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $7,577.75 | 02/04/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Pan-Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab | No dispute reported | 06/30/2026 | 819885891 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,000.00 | 02/02/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Phase III 1L GBM Unmethylated MGMT nivo mono RT | No dispute reported | 06/30/2026 | 819885939 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $500.00 | 02/02/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Phase IIIB Dose Comparison N3 I1 vs I3 N1 in melanoma | No dispute reported | 06/30/2026 | 819885951 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,663.60 | 01/21/2021 | Covered Recipient Teaching Hospital Lehigh Valley | A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC) | No dispute reported | 06/30/2026 | 819885991 |
| Principal investigator 1 | ABBVIE INC. | $1,417.00 | 01/14/2021 | Covered Recipient Teaching Hospital LEHIGH VALLEY | A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC) | No dispute reported | 06/30/2026 | 792386171 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,390.00 | 01/04/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Phase III Adjuvant Melanoma Monotherapy | No dispute reported | 06/30/2026 | 819885849 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,879.00 | 01/04/2021 | Covered Recipient Teaching Hospital Lehigh Valley | Phase IIB Hodgkins Lymphoma | No dispute reported | 06/30/2026 | 819885855 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $20,444.00 | 01/04/2021 | Non-covered Recipient Entity Memorial Sloan Kettering Cancer Center | Phase III 1L Metastatic RCC Nivo Ipi Cabo | No dispute reported | 06/30/2026 | 819896765 |